Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2301-2313

  Karalis, Ioannis K ^a   Bergheanu, Sandrin C ^a   Wolterbeek, Ron ^a   Dallinga Thie, Geesje M ^b   Hattori, Hiroaki ^c   Van Tol, Arie ^d   Liem, Anho H ^e   Jukema, J Wouter ^a,f  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BML   (Japan)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Oosterschelde Hospital   (Netherlands)

^f Durrer Center for Cardiogenetic Research   (Netherlands)

Author keywords

Apolipoproteins; C reactive protein; Enzymes; Hydroxymethylglutaryl CoA reductase inhibitors; Lipid metabolism

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENZYME; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERCELLULAR ADHESION MOLECULE 1; LIPID TRANSFER PROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEINS; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYMES; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOPROTEINS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PYRIMIDINES; PYRROLES; SULFONAMIDES;

EID: 77956739905     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.509264     Document Type: Article

References (59)

1. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504
2. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
3. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertrigly-ceridemia. JAMA 1996;275:128-133
4. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of ator-vastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-587 (Pubitemid 28182422)
5. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-160
6. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91:2528-2540
7. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565
8. Girona J, La Ville AE, Solà R, et al. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999;83:846-851
9. Llevadot J, Murasawa S, Kureishi Y, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Investig 2001;108:399-405
10. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30:1212-1217
11. Jukema JW, Liem A-H, Dunselman PHJM, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin 2005;21:1865-1874
12. Bergheanu SC, Reijmers T, Zwinderman AH, et al. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008;24:2477-2487
13. Bergheanu SC, Van Tol A, Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235-2240
14. Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 2006;49:1505-1511
15. Kujiraoka T, Hattori H, Miwa Y, et al. Serum apolipoprotein J in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 2006; 13:314-322
16. Nagano M, Yamashita S, Hirano K, et al. Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay. J Lipid Res 2002;43:1011-1018
17. Oka T, Kujiraoka T, Ito M, et al. Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem 2000;46:1357-1364
18. Speijer H, Groener JE, van Ramshorst E, et al. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991;90:159-168
19. Dallinga-Thie GM, van Tol A, Hattori H, et al. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorva-statin: a role for apolipoprotein E? Diabetes 2006;55:1491-1496 (Pubitemid 44195392)
20. Blank ML, Lee T, Fitzgerald V, et al. A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem 1981;256:175-178
21. van Hoek M, Dallinga-Thie GM, Steyerberg EW, et al. Diagnostic value of post-heparin lipase testing in detecting common genetic variants in the LPL and LIPC genes. Eur J Hum Genet 2009;17:1386-1393
22. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640-648
23. Kappelle PJWH, Dallinga-Thie GM, Dullaart RPF. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. Biochimica Et Biophysica Acta 2010;1801:89-94
24. Meisinger C, Loewel H, Mraz W, et al. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005;26:271-278
25. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-2033
26. Kawakami A, Yoshida M. Remnant lipoproteins and atherogenesis. J Atherosclerosis Thromb 2005;12:73-76
27. Zheng X-Y, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007;48:1673-1680
28. Nozue T, Michishita I, Ito Y, et al. Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia. J Atherosclerosis Thromb 2008; 15:146-153
29. Zhang B, Matsunaga A, Rainwater DL, et al. Effects of ROSuvastatin on electronegative LDL as characterized by CapillARY isotachophoresis: The ROSARY study. J Lipid Res 2009;50:1832-1841
30. Johnson WJ, Kilsdonk EP, van Tol A, et al. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP-AI/AII. J Lipid Res 1991;32:1993-2000
31. Huang Y, von Eckardstein A, Wu S, et al. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995;15:1412-1418
32. Nieminen T, Kä hö nen M, Viiri LE, et al. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008;9:1475-1486
33. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipo-protein metabolism. Curr Opin Lipidol 2001;12:297-304
34. Tai ES, Ordovas JM. Clinical significance of apolipoprotein A5. Curr Opin Lipidol 2008;19:349-354
35. Kawakami A, Osaka M, Tani M, et al. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 2008;118:731-742
36. Miyata M, Biro S, Kaieda H, et al. Apolipoprotein J/clusterin is induced in vascular smooth muscle cells after vascular injury. Circulation 2001; 104:1407-1412
37. Poulakou MV, Paraskevas KI, Vlachos IS, et al. Effect of statins on serum apolipoprotein J and paraoxonase-1 levels in patients with ischemic heart disease undergoing coronary angiography. Angiology 2008;59:137-144
38. Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol 2006;21:345-352
39. Boekholdt SM, Kuivenhoven J-A, Wareham NJ, et al. Plasma levels of cho-lesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004;110:1418-1423
40. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 2010;31:149-164
41. De Haan W, de Vries-van der Weij J, van der Hoorn JW, et al. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflam-matory lesions than atorvastatin. Circulation 2008;117:2515-2522
42. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310
43. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010; 31:480-488
44. Huuskonen J, Ekström M, Tahvanainen E, et al. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000; 151:451-461
45. Schlitt A, Blankenberg S, Bickel C, et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J Lipid Res 2009;50:723-729
46. Jonkers IJ, Smelt AH, Hattori H, et al. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy. J Lipid Res 2003;44:1462-1469
47. Dallinga-Thie GM, van Tol A, Dullaart RPF. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. Biochimica Et Biophysica Acta 2009;1791: 714-718
48. Carlquist JF, Muhlestein JB, Anderson JL. Lipoprotein-associated phospho-lipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target. Expert Rev Molecular Diagnostics 2007;7:511-517
49. Napoli C, Leccese M, Palumbo G, et al. Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia. Coron Artery Dis 1998;9:257-264
50. Kassai A, Illyés L, Mirdamadi HZ, et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2007;40:1-5
51. Sviridov D, Hoang A, Ooi E, et al. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 2008;197:732-739
52. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipi-demia. Diabetes Care 2001;24:1335-1341
53. Berk-Planken IIL, Hoogerbrugge N, Stolk RP, et al. Atorvastatin dose-depen-dently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 2003;26:427-432
54. Blanco-Colio LM, Martín-Ventura JL, de Teresa E, et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a sub-study of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007;153:881-888
55. Sejda T, Jedliè ková V, Svandová E, et al. The effect of fluvastatin on cICAM-1 as a biomarker of endothelial dysfunction in patients with dyslipidemia. Int Angiol 2006;25:414-417
56. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100:230-235
57. Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006;114:281-288
58. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28
59. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373:1175-1182